Association between insulin-like growth factor-2 expression and prognosis after transcatheter arterial chemoembolization and octreotide in patients with hepatocellar carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3191-3194

  Xiong, Zheng Ping ^a   Huang, Fang ^b,c   Lu, Meng Hou ^c  

^a HUNAN CANCER HOSPITAL   (China)

^b THE THIRD XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

HCC; IGF 2; Metastasis; Octreotide; Prognosis; TACE

Indexed keywords

EID: 84873583645     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3191     Document Type: Article

References (19)

1. Bao Y, Feng WM, Tang CW, et al (2012). Endostatin Inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization. Hepatogastroenterology, 28, 59.
2. Barbare JC, Bouché O, Bonnetain F, et al (2009). Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer, 45, 1788-97.
3. El Tayebi HM, Salah W, El Sayed IH, et al (2011). Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. Biomarkers, 16, 346-54.
4. Facciorusso A, Nacchiero MC, Rosania R, et al (2012). Pathways and gene expression profiles in hepatocellular carcinoma. Minerva Gastroenterol Dietol, 58, 35- 48.
5. Finn RS (2012). Advanced HCC: emerging molecular therapies. Minerva Gastroenterol Dietol, 58, 25-34.
6. Guo TK, Hao XY, Ma B, et al (2009). Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol, 135, 1685-92.
7. Hasskarl J, Kaufmann M, Schmid HA (2011). Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol, 7, 895-913.
8. Jiang J, Deng L, He L, et al (2011). Expression, purification, refolding, and characterization of octreotide-interleukin-2: a chimeric tumor-targeting protein. Int J Mol Med, 28, 549-56.
9. Ji XQ, Ruan XJ, Chen H, et al (2011). Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit, 17, 169-76.
10. Laznicek M, Laznickova A, Maecke HR (2012). Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs. Anticancer Res, 32, 761-6.
11. Niu J, Su Z, Xiao Y, et al (2012).Octreotide-modified and pH-triggering polymeric micelles loaded with doxorubicin for tumor targeting delivery. Eur J Pharm Sci, 45, 216-26.
12. Prete SD, Montella L, Caraglia M, et al (2010). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol, 66, 837-44.
13. Qian J, Yao D, Dong Z, et al (2010). Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol, 134, 799-806.
14. Rehem RN, El-Shikh WM (2011). Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology, 58, 949-54.
15. Salvatore DP, Liliana M, Michele C, et al (2010). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So. LAR. study. Cancer Chemother Pharmacol, 66, 837- 44.
16. Wachter DL, Kristiansen G, Soll C, et al (2012). Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology, 60, 278-86.
17. Wang Z, Zhou J, Fan J, et al (2009). Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma Journal of Cancer Research and Clinical. Oncology, 135, 715-22.
18. Xiang ZL, Zeng ZC, Fan J, et al (2011). Gene expression profiling of fixed tissues identified hypoxia-inducible factor- 1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res, 17, 5463-72.
19. Zhang Y, Zhang H, Wang X, et al (2012). The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials, 33, 679-91.